(24 May 2021) Tofacitinib-effective and safe for managing the cytokine release syndrome in COVID-19
Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19 https://doi.org/10.1016/j.pupt.2021.102039 Thirty-two patients who received tofacitinib (TOF group) and 30 patients who did not receive any anti-cytokine drugs (control [CON] group) were enrolled. Mortality and the incidence of admission to… Continue reading "(24 May 2021) Tofacitinib-effective and safe for managing the cytokine release syndrome in COVID-19"